172733-07-2

Upstream product

• 164082-80-8 1-benzyl-2-ethyl-4-methoxy-1H-indole 
• 96-32-2 bromoacetic acid methyl ester 
• 172733-06-1 1-benzyl-2-ethyl-1H-indol-4-ol 

Downstream Products

• 948553-63-7 (1-Benzyl-3-chlorooxalyl-2-ethyl-1H-indol-4-yloxy)-acetic acid methyl ester 
• 1027082-05-8 (1-Benzyl-2-ethyl-1H-indol-4-yloxy)-acetic acid hydrazide 
• 185298-46-8 2-(1-Benzyl-2-ethyl-1H-indol-4-yloxy)-acetamide 
• 172732-68-2 ((3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)acetic acid 
• 185298-58-2 2-(1-Benzyl-4-carbamoylmethoxy-2-ethyl-1H-indol-3-yl)-2-oxo-acetamide 
• 172733-08-3 [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid methyl ester 
• 12125-02-9 ammonium chloride 

Relevant academic research and scientific papers

PHARMACEUTICAL COMPOSITIONS CONTAINING THE PHOSPHOLIPASE INHIBITOR SODIUM 3-(2-AMINO-1,2-DIOXOETHYL)-2-ETHYL-1-PHENYLMETHYL)-1H-INDOL-4-YL]OXY]ACETATE

A lyophilized pharmaceutical composition is described which contains Sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1H-indol-4-yl]oxy]acetate, a Solubilizer, and a Stabilizer. Such compositions are storage stable and readily dissolve in aqueous medium to give injectable solution for treatment of sepsis, etc.

Novel sPLA2 inhibitors

A class of novel indole is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.

Process for preparing toluenesulfinates

A process for preparing novel compounds useful in the preparation of 1H-indole-3-glyoxamides.

Novel sPLA2 inhibitors

A class of novel indole is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.

Combination therapy for the treatment of inflammatory and respiratory diseases

A pharmaceutical composition for the treatment of Inflammatory Disease or Respiratory Disease in mammals, which comprises, as active ingredients, a neutrophil elastase inhibitor and an sPLA2 inhibitor.

SPLA2 inhibitor compounds for treatment of disease

The present invention is directed to compounds for treating inflammatory bowel disease. More specifically, the present invention is directed to 1H-indole-3-glyoxyamide compounds a sPLA2inhibitors for treating inflammatory bowel disease.

Method for the treatment of stroke using N-heterocyclic glyoxlyamide compounds

A method and composition for the treatment and/or prevention of stroke is disclosed using N-heterocyclic glyoxamide compounds having the following general formula: wherein X, E, F, R11, R12, R14, R15, R16and R17are as defined herein.

Process for preparing 4-substituted-1h-indole-3-glyoxamides

A process for preparing 1H-indole-3-glyoxamides useful for inhibiting SPLA2and novel intermediates useful in the preparation of such compounds.

Morpholino-n-ethyl ester derivative of an indole sPLA2 inhibitor

The compound, ((3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)acetic acid morpholino-N-ethyl ester, is disclosed together with its use as a highly bioavailable indole compound for inhibiting sPLA2 mediated release of fatty acids fo

Method for treatment of chronic bronchitis using indole compounds

A method is disclosed for the treatment of chronic bronchitis by administering to a mammal in need thereof a therapeutically effective amount of a 1H-indole-3-glyoxylamide compound.